Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis. (April 2019)

• Record Type: Journal Article
• Authors: DiRisio, Aislyn C.; Harary, Maya; Muskens, Ivo S.; Yunusa, Ismaeel; Gormley, William B.; Aglio, Linda S.; Smith, Timothy R.; Connors, Jean M.; Mekary, Rania A.; Broekman, Marike L.D.
• Is Part Of: Journal of clinical neuroscience. Volume 62(2019)
• Page Start: 188
• Page End: 194
• Publication Date: 2019-04
• Subjects: Cerebral hemorrhage -- Anticoagulants -- Coumarins -- Direct oral anticoagulants; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2018.11.032
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Intraparenchymal hemorrhage (IPH) is a feared complication of oral anticoagulation. DOAC-IPH was not associated with increased mortality or hematoma expansion compared to VKA-IPH. DOAC-IPH may be associated with a smaller hematoma volume as compared to VKA-IPH. Abstract: Direct Oral Anticoagulants (DOAC) are increasingly used as an alternative to vitamin-K antagonists (VKA) for anticoagulation and have shown lower rates of intracranial hemorrhage; however, there is disagreement in the literature over the outcomes of the intraparenchymal hemorrhages (IPH) associated with DOACs, and clinical concern regarding the lack of standardized reversal strategies for DOACs. Thus, the aim of this meta-analysis was to compare mortality, hematoma volume, and risk of hematoma expansion in patients who developed an IPH on DOACs versus VKA. A systematic review of the literature was conducted in accordance with the PRISMA guidelines. Studies were selected that reported on mortality, hematoma expansion, and hematoma volume in DOAC-associated IPH. Pooled risk ratios (RR) were calculated for mortality and hematoma expansion and pooled mean difference (MD) was calculated for hematoma volume (ml) using random-effect models. 15 studies reporting on 1238 patients were included in the systematic review. Eleven of these compared DOAC-IPH to VKA-IPH and were pooled quantitatively. DOAC-IPH was not associated with increased mortality risk (RR: 0.95, 95%-CI: 0.72 –1.27) or increased hematoma expansion risk (RR: 0.92; 95%-CI: 0.75–1.12) compared to VKA-IPH. The hematoma volume of DOAC- IPH was statistically significantly smaller than VKA-IPH (MD: −12.14 ml; 95%-CI: −15.38; −8.89). In conclusion, DOAC-IPH was not associated with increased mortality or hematoma expansion compared to VKA-IPH and may be associated with a smaller hematoma volume.